Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 17/20 | 0.39 |
| ▸ | AKT2 | P31751 | 9/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1907331 | 1.00 | AURKA (0.46) | AURKAAKT1AKT2EGFRJAK2 | |
| SCHEMBL1901319 | 0.88 | AURKA (0.44) | AURKAEGFRJAK2LCKSRC | |
| SCHEMBL1902277 | 0.87 | AURKA (0.46) | AURKAAKT1AKT2 | |
| SCHEMBL1901287 | 0.87 | AURKA (0.46) | AURKAAKT1AKT2 | |
| SCHEMBL1901289 | 0.87 | AURKA (0.46) | AURKAAKT1AKT2 | |
| SCHEMBL1901112 | 0.86 | CHEK1 (0.43) | AURKAAKT1AKT2 | |
| SCHEMBL1905142 | 0.86 | AKT1 (0.41) | AKT1AKT2 | |
| Hydrochloric Acid SCHEMBL14119158 | 0.86 | CHEK1 (0.42) | AURKAAKT1AKT2 | |
| SCHEMBL1904665 | 0.85 | AKT1 (0.40) | AKT1AKT2 | |
| Hydrochloric Acid SCHEMBL1901271 | 0.85 | AKT1 (0.41) | AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | claimed |
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | AURKA 527/4885AKT1 1/4885AKT2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.